Two Sigma Investments LP Purchases 131,916 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

Two Sigma Investments LP lifted its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 266.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 181,471 shares of the biopharmaceutical company's stock after purchasing an additional 131,916 shares during the period. Two Sigma Investments LP owned about 0.37% of Puma Biotechnology worth $553,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Two Sigma Advisers LP grew its holdings in shares of Puma Biotechnology by 22.3% in the fourth quarter. Two Sigma Advisers LP now owns 196,900 shares of the biopharmaceutical company's stock worth $601,000 after purchasing an additional 35,900 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Puma Biotechnology in the fourth quarter worth $36,000. Nuveen Asset Management LLC lifted its stake in Puma Biotechnology by 41.4% in the fourth quarter. Nuveen Asset Management LLC now owns 79,101 shares of the biopharmaceutical company's stock worth $241,000 after acquiring an additional 23,179 shares during the period. Graham Capital Management L.P. purchased a new stake in Puma Biotechnology in the fourth quarter worth $33,000. Finally, D. E. Shaw & Co. Inc. lifted its stake in Puma Biotechnology by 287.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 222,608 shares of the biopharmaceutical company's stock worth $679,000 after acquiring an additional 165,220 shares during the period. Institutional investors own 61.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PBYI shares. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, February 28th. Wall Street Zen raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd.

Puma Biotechnology Trading Up 1.9%

Shares of NASDAQ:PBYI opened at $3.72 on Monday. Puma Biotechnology, Inc. has a 12-month low of $2.23 and a 12-month high of $4.13. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The company has a market cap of $184.63 million, a PE ratio of 7.75 and a beta of 1.29. The stock has a 50 day moving average of $3.11 and a 200 day moving average of $3.10.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.